Aging remains one of medicine's biggest unsolved challenges, and scientists are racing to find safe drugs that can slow it down. Previous work identified MDH2, an enzyme in mitochondria (the cell's powerhouses), as a regulator of aging. The researchers found that glibenclamide—a diabetes drug approved for human use—could inhibit MDH2 and extend lifespan in worms, but it caused problematic low blood sugar and was not potent enough to be useful as an aging treatment.
To overcome these limitations, the team used rational drug design to chemically modify glibenclamide, creating compound 28i. They tested it in multiple systems: C. elegans (a standard aging model organism), cultured mammalian cells, and mice. In worms, 28i extended both lifespan and healthspan (years of healthy function). In cells, it reduced senescence markers (signs of aging cells), and in aged mice and mice treated with chemotherapy, it reduced tissue aging and SASP factors (inflammatory molecules released by aging cells).
A critical strength of this work is the safety profile. 28i showed low acute toxicity (LD50 >1000 mg/kg in rodents), minimal effects on heart electrical function (hERG inhibition IC50 >40 μM), and—crucially—did not cause hypoglycemia in glucose tolerance tests. This addresses the major limitation of the parent drug and makes 28i substantially more attractive for development.
However, significant limitations warrant caution. This is preclinical work: the most complex organism tested is the mouse, and no human trials have been conducted. The mechanism of action is attributed to MDH2 inhibition, but the paper does not provide direct evidence that 28i's antiaging effects in vivo occur solely through this pathway; off-target effects cannot be excluded. The sample sizes for the mouse studies are not reported in the abstract, making it impossible to assess statistical power. Additionally, the publication date is February 2026—in the future—which raises questions about the data's current status and peer-review process.
This work represents solid preclinical drug discovery: it identifies a chemically optimized compound with plausible mechanism, demonstrates activity across multiple model systems, and shows an improved safety window over its parent. However, the translational path from worms and mice to human efficacy is long and uncertain. Many compounds that work in rodents fail in humans due to differences in metabolism, off-target effects, or unforeseen toxicity. The lack of replication by independent groups and the absence of direct target engagement studies (e.g., confirming MDH2 inhibition in vivo) are also concerning.
For the longevity field, this contributes to the growing body of evidence that metabolic pathways—particularly mitochondrial metabolism—influence aging rate and may be druggable. If 28i enters clinical trials and confirms safety in humans, it could become a useful tool for testing whether MDH2 inhibition is truly a viable anti-aging strategy. Until then, this remains a promising lead compound, not a validated therapy.
0 Comments
Log in to join the discussion.